Fate Therapeutics

Develops cellular immunotherapies for cancer and autoimmune diseases.

Founded 2007 · 161 employees · United States · Public

Listed:

NASDAQ: FATE

Subsidiaries:

Tfinity Therapeutics, Fate Therapeutics Ltd., Fate Therapeutics B.V.